Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
13.9M
-
Shares change
-
+1.57M
-
Total reported value, excl. options
-
$446M
-
Value change
-
+$47.6M
-
Put/Call ratio
-
0.43
-
Number of buys
-
87
-
Number of sells
-
-70
-
Price
-
$32.00
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q2 2018
193 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2018.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.9M shares
of 14.4M outstanding shares and own 96.67% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.06M shares), KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (1.6M shares), DIMENSIONAL FUND ADVISORS LP (978K shares), VANGUARD GROUP INC (853K shares), Bank of New York Mellon Corp (503K shares), MORGAN STANLEY (502K shares), FIRST MANHATTAN CO (493K shares), STATE STREET CORP (489K shares), WELLINGTON MANAGEMENT GROUP LLP (383K shares), and DEUTSCHE BANK AG\ (371K shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.